Search Result

Results for "

cardiovascular risks

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Apolipoprotein (2) Apoptosis (3) Bacterial (3) Cannabinoid Receptor (1) COX (1) Dopamine β-hydroxylase (2) Endogenous Metabolite (1) Epoxide Hydrolase (1) Fungal (1) PPAR (1) Reactive Oxygen Species (1)
By Research Areas:	Cardiovascular Disease (17) Infection (3) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (4)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131981

TP0586532 1 Publications Verification	Bacterial	Infection
TP0586532 is a non-hydroxamate LpxC inhibitor (IC₅₀=0.101 μM). TP0586532 as a compound with a low cardiovascular risk that is effective against K. pneumoniae, including resistant strains . TP0586532 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103372

GSK264220A	Others	Cardiovascular Disease
GSK264220A is a potent endothelial lipase inhibitor with IC₅₀ of 16 nM. GSK264220A has the potential to decrease the risk of cardiovascular disease .

HY-14838A

Etamicastat hydrochloride BIA 5-453 hydrochloride	Dopamine β-hydroxylase	Cardiovascular Disease
Etamicastat hydrochloride (BIA 5-453 hydrochloride) is a potent and reversible dopamine-β-hydroxylase (DBH) inhibitor with an IC₅₀ value of 107 nM . Etamicastat can be used in the research of cardiovascular diseases .

HY-N13235

Garlic Extract	Others	Cardiovascular Disease
Garlic Extract is a garlic extract, and its components include: Allicin. Garlic Extract is beneficial to cardiovascular disease and has the potential to reduce the risk of cardiovascular disease. Garlic Extract can effectively reduce total cholesterol, low-density lipoprotein levels and improve high-density lipoprotein levels. .

HY-N4271

Protogracillin	Others	Cardiovascular Disease
Protogracillin is a steroidal saponin isolated from Dioscorea zingiberensis Wright (DZW). Steroidal saponins from DZW rhizomes have the potential to reduce the risk of cardiovascular diseases by anti-thrombotic action .

HY-B0835

Fenobucarb	Apoptosis	Cardiovascular Disease Neurological Disease
Fenobucarb is a carbamate insecticide. Fenobucarb induces zebrafish developmental neurotoxicity through pathways involved in inflammation, oxidative stress, degeneration and apoptosis. Fenobucarb is a possible risk factor to cardiovascular and cerebrovascular systems in animals .

HY-N3307

(+)-Medioresinol	Bacterial Fungal Reactive Oxygen Species Apoptosis	Infection Cardiovascular Disease Neurological Disease
(+)-Medioresinol is a furofuran type lignan with antifungal, antibacterial and lesishmanicidal activities. (+)-Medioresinol leads to intracellular ROS accumulation and mitochondria-mediated apoptotic cell death in Candida albicans. (+)-Medioresinol can reduce the cardiovascular disease risk .

HY-169001

5-HT2A/5-HT2C inverse agonist 1	5-HT Receptor	Neurological Disease
5-HT2A/5-HT2C inverse agonist 1 is a potent and dual 5-HT2A and 5-HT2C receptor inverse agonist with a hERG inhibitions, thus avoiding cardiovascular risks. 5-HT2A/5-HT2C inverse agonist 1 shows significant antipsychotic efficacy in the MK-801 (HY-15084B)-induced mouse model. 5-HT2A/5-HT2C inverse agonist 1 is promising for research of psychosis .

HY-14838

Etamicastat BIA 5-453	Dopamine β-hydroxylase	Cardiovascular Disease
Etamicastat (BIA 5-453) is a potent and reversible dopamine-β-hydroxylase (DBH) inhibitor with an IC₅₀ value of 107 nM . Etamicastat can be used in the research of cardiovascular diseases .

HY-153491

Olezarsen ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx	Apolipoprotein	Cardiovascular Disease
Olezarsen is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.

HY-153491A

Olezarsen sodium ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium	Apolipoprotein	Cardiovascular Disease
Olezarsen sodium is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.

HY-14753

Rosonabant	Cannabinoid Receptor	Cardiovascular Disease Metabolic Disease
Rosonabant is a selective antagonist for cannabinoid receptor (CB1 receptor), which reduces body weight and improves improves the risk of obesity-related cardiovascular metabolic diseases. Rosonabant exhibits adverse side effect, such as nausea and mental disorder .

HY-142619

TP0586352	Bacterial	Infection
TP0586352 is a LpxC inhibitor that is effective against carbapenem-resistant Klebsiella pneumoniae and does not pose a cardiovascular risk. TP0586352 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W709553

Glyceryl Triformate Triglyceride	Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
Glyceryl Triformate (Triglyceride) is the major form of storage and transport of fatty acids within cells and in the plasma. Glyceryl Triformate forms lipoproteins with cholesterol ester, and participates in the blood circulation. Glyceryl Triformate can lead to hypertriglyceridemia (HTG), which increases the risk of atherosclerotic cardiovascular disease (ASCVD) and pancreatitis .

HY-B0835R

Fenobucarb (Standard)	Apoptosis	Cardiovascular Disease Neurological Disease
Fenobucarb (Standard) is the analytical standard of Fenobucarb. This product is intended for research and analytical applications. Fenobucarb is a carbamate insecticide. Fenobucarb induces zebrafish developmental neurotoxicity through pathways involved in inflammation, oxidative stress, degeneration and apoptosis. Fenobucarb is a possible risk factor to cardiovascular and cerebrovascular systems in animals .

HY-167743

Platelet aggregation-IN-2	Others	Cardiovascular Disease
Platelet aggregation-IN-2 is an anti-platelet aggregation agent with significant anticoagulant activity. Platelet aggregation-IN-2 can inhibit platelet aggregation reaction and reduce the risk of thrombosis. The application of Platelet aggregation-IN-2 can potentially be used for the prevention and suppression of cardiovascular diseases .

HY-146704

COX-2/sEH-IN-1	Epoxide Hydrolase COX	Cardiovascular Disease
COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC₅₀ values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks .

HY-14728

Aleglitazar R1439; RO0728804	PPAR	Metabolic Disease
Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC₅₀s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes .

HY-117912

TRC210258	Others	Cardiovascular Disease
TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .

Cat. No.	Product Name

HY-L046

Anti-Cardiovascular Disease Compound Library	1,695 compounds
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk. MCE supplies a unique collection of 1,695 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Anti-Cardiovascular Disease Compound Library

1,695 compounds

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.

MCE supplies a unique collection of 1,695 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

HY-L043

Lipid Compound Library	1,439 compounds
Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies. MCE supplies a unique collection of 1,439 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

Lipid Compound Library

1,439 compounds

Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies.

MCE supplies a unique collection of 1,439 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

HY-L145

Antihypertensive Compound Library	648 compounds
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death. Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs). MCE offers a unique collection of 648 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Antihypertensive Compound Library

648 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 648 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

C-Reactive Protein (CRP) (201-206)	Peptides	Cardiovascular Disease Inflammation/Immunology
C-Reactive Protein (CRP) 201-206 is the 201-206 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis .

C-Reactive Protein (CRP) (77-82)	Peptides	Cardiovascular Disease Inflammation/Immunology
C-Reactive Protein (CRP) 77-82 is the 77-82 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis .

Protogracillin	Cardiovascular Disease other families Classification of Application Fields Source classification Plants Disease Research Fields Steroids	Others
Protogracillin is a steroidal saponin isolated from Dioscorea zingiberensis Wright (DZW). Steroidal saponins from DZW rhizomes have the potential to reduce the risk of cardiovascular diseases by anti-thrombotic action .

(+)-Medioresinol	Cardiovascular Disease Structural Classification Neurological Disease Classification of Application Fields Oleaceae Fraxinus mandshurica Rupr. Source classification Phenols Polyphenols Plants Disease Research Fields	Bacterial Fungal Reactive Oxygen Species Apoptosis
(+)-Medioresinol is a furofuran type lignan with antifungal, antibacterial and lesishmanicidal activities. (+)-Medioresinol leads to intracellular ROS accumulation and mitochondria-mediated apoptotic cell death in Candida albicans. (+)-Medioresinol can reduce the cardiovascular disease risk .

Cat. No.	Product Name		Classification